Here are the latest stories being discussed in biopharma today:

Amylyx Prepares for Crucial Phase III Trial for Controversial ALS Drug

Amylyx Pharmaceuticals is gearing up for a make-or-break Phase III trial aimed at addressing the ongoing controversy surrounding its ALS drug. The results, expected to be announced by the end of June, could be a deciding factor in the drug’s future, which was approved by the FDA in 2022 on the back of a single mid-stage study.

Bayer in Defence of Current Structure Amidst Job Cuts and Business Challenges

Bayer executives recently defended their decision to maintain the company’s current conglomerate structure, focusing instead on addressing issues across its pharma, consumer health, and crop science units. With various challenges to navigate over the next two to three years, the company noted that they plan to reduce “substantial” positions that they deem as hindrances.

Regenxbio Shares Promising Early Results for Duchenne Gene Therapy

Regenxbio has shared early biomarker results from a Duchenne muscular dystrophy patient who received a higher dose of its gene therapy. The findings indicate a significant reduction in creatinine kinase levels and a strong dysfermin expression from the treatment. Regenxbio looks to start a pivotal study later in the year to include a wider age range of boys.

Roche, Alnylam’s Zilebesiran Succeeds in Another Phase II Hypertension Trial

Alnylam Pharmaceuticals’ RNAi therapy, in collaboration with Roche, successfully reduced blood pressure in a Phase II hypertension trial. The test is the second clinical success for the treatment, marking another positive milestone for the partnership between Alnylam and Roche, which started in July.

BridgeBio Proceeds with $250M Offering While Bayer Buys Treatment Rights

While BridgeBio announced plans to raise $250 million in stock sale, Bayer disclosed its purchase of the European rights to acoramidis, BridgeBio’s treatment drug candidate for ATTR amyloidosis with cardiomyopathy.

Bayer Remains Intact, Prioritizes Fixing Imperfections

Bayer is not ready to disintegrate its pharma, consumer and crop science divisions, instead focusing on the areas in need of improvement and creating strategic flexibility for the future.